Health News Releases

  • Today May 23
August 21, 2014 10:35
Quintiles CEO to Present at the Morgan Stanley Global Healthcare Conference
Quintiles CEO Tom Pike will present at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 in New York City at the Grand Hyatt Hotel. The Quintiles presentation will begin
August 20, 2014 13:50
Expression Analysis Announces 2014 Grant Program
Expression Analysis (EA), a Quintiles company, today announced that it is co-sponsoring a grant program that provides scientists with leading-edge products and services to advance genomics research. I
August 20, 2014 13:40
Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate
Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristin
August 19, 2014 17:45
First patients enrolled in study to evaluate dabigatran etexilate after PCI with stenting
INGELHEIM, Germany--(BUSINESS WIRE)-- For Non-US/Non-UK/Non-Canadian Media Boehringer Ingelheim today announces that the first patients have been enrolled in the company’s new international phas
August 19, 2014 13:40
Provectus Signs Memorandum of Understanding with Sinopharm-China State Institute of Pharmaceutical Industry, and Sinopharm A-THINK Pharmaceutical Co., Ltd.
Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it entered into a
August 18, 2014 14:00
Catalent Confirms the Appointment of Two Senior Healthcare Executives to Its Board of Directors
Catalent, Inc. (NYSE:CTLT), the global leader in drug development solutions and advanced delivery technologies for pharmaceutical, biologic, and consumer health products, today announced that it has a
Hyun Joon Moon MD, PhD.
August 12, 2014 18:06
Convenient Real No-Scalpel Vasectomy(CRNSV) techniques developed at CR CENTER in South Korea cited in an American Urology Association guideline
Vasectomy techniques and an associated device developed by Dr. Hyun Joon Moon at CR vas & microsurgery center (Seoul, South Korea) have been formally cited in an American Urology Association guideline
August 08, 2014 13:50
Terumo BCT Announces Collaboration to Evaluate Clinical Cell Production Using Quantum System
Terumo BCT’s Quantum® Cell Expansion System (http://goo.gl/O8RrZ4) is now under evaluation by Athersys, Inc., a biopharmaceutical company dedicated to the research and development of stem cell therapi
August 07, 2014 13:50
European Commission publishes approval of Octapharma’s human cell line recombinant FVIII (Nuwiq®) across all age groups in haemophilia A
The European Commission has published approval of Octapharma’s Nuwiq® (simoctocog alfa) for the treatment and prophylaxis of bleeding in all age groups with haemophilia A (congenital factor VIII [FVII
August 01, 2014 13:45
Panasonic's Healthcare Solutions Streamline Medical Treatment
Under the theme of “Providing optimal healthcare for each individual,” Panasonic Healthcare Co., Ltd. showcased its latest solutions at the International Modern Hospital Show 2014, which was held at t
August 01, 2014 10:05
Catalent, Inc. Announces Pricing of Its Initial Public Offering
Catalent, Inc. (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the pricing of i
July 31, 2014 11:00
Harlan Provides Expertise for Biologics and Biosimilars
Harlan Laboratories, Ltd. (www.harlan.com), a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS), http://goo.gl/At862O) business, is prep
July 25, 2014 09:50
UpToDate Adds Palliative Care as a Specialty
Wolters Kluwer Health (http://goo.gl/o2rWK), a leading global provider of information for healthcare professionals and students, announced today that it has added Palliative Care to UpToDate®, its evi
July 24, 2014 10:20
PLEGRIDY™ (Peginterferon beta-1a) Approved in the European Union for the Treatment of Multiple Sclerosis
Today Biogen Idec (NASDAQ: BIIB) announced that the European Commission (EC) has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a) as a treatment for adults with relapsing-remitti
July 23, 2014 13:20
Iroko Pharmaceuticals Continues to Expand Commercialization of ZORVOLEX® With New Strategic Agreement in Latin America
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that its affiliate, Iroko Pharmaceuticals Inc., signed a licensin
July 18, 2014 13:10
Terumo BCT Opens Manufacturing Facility in Vietnam
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced the opening of its new 91,440-square-meter facility near Ho Chi Minh City, Vietnam. The
July 18, 2014 10:30
Boehringer Ingelheim’s investigational therapy nintedanib* receives the first FDA Breakthrough Therapy designation in IPF
For non-U.S. Media Only Boehringer Ingelheim today announced that for the first time the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation for a treatment in idiopa
July 16, 2014 11:50
Iroko Pharmaceuticals Announces New Strategic Agreement to Commercialize ZORVOLEX® in Brazil
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that its affiliate, Iroko Pharmaceuticals Inc., has signed a lice
July 15, 2014 21:00
Harlan and Fluofarma Sign Strategic Collaboration Agreement
Harlan Laboratories, Ltd. (www.harlan.com), a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS, http://goo.gl/At862O) business, and Fluo
July 10, 2014 10:55
Celgene Reports Results from the Phase III POSTURE Study Evaluating Oral OTEZLA® in Ankylosing Spondylitis
Celgene Corporation (NASDAQ:CELG) today announced results of its phase III POSTURE study evaluating OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with acti
July 09, 2014 11:45
Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients
For media outside of the US/UK only Summary: Acute Myeloid Leukaemia (AML) is an aggressive and devastating blood cancer.1,2 It predominantly affects people over 60 and is one of the most common
July 09, 2014 09:40
Iroko Pharmaceuticals Announces First International Filing for ZORVOLEX®
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced the company affiliate’s first regulatory submission outside of th
July 09, 2014 02:10
Morinaga Milk Industry Co., Ltd. Unveils New Research Demonstrating the Superiority of Human Residential Bifidobacteria
Morinaga Milk Industry Co., Ltd. (www.morinagamilk.co.jp/english) (TOKYO:2264), the second largest dairy product company in Japan, today announced that Morinaga has discovered differences in potential
July 07, 2014 18:00
WIN Consortium in Personalized Cancer Medicine Welcomes Six New Member Organizations during the WIN 2014 Symposium
The Worldwide Innovative Networking (WIN) Consortium in personalized cancer medicine proudly announces that six new organizations were approved as WIN Consortium members during the Consortium’s 2014 W
July 03, 2014 07:00
U.S. Food & Drug Administration Grants Orphan Drug Designation for Galderma’s Trifarotene Molecule in the Treatment of Congenital Ichthyosis
Galderma announces that the U.S. FDA granted Orphan Drug Designation status for the company’s trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma plans to
25 per page50 per page75 per page100 per page